コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 al pro-apoptotic effect of dexamethasone and fluticasone furoate.
2 95% CI 0.75-1.14]) with similar findings for fluticasone furoate (0.90 [0.72-1.11]) and vilanterol (0
3 , vilanterol (25 mug), or the combination of fluticasone furoate (100 mug) and vilanterol (25 mug).
4 locks to receive once daily inhaled placebo, fluticasone furoate (100 mug), vilanterol (25 mug), or t
5 ere pretreated with either cetirizine 10 mg, fluticasone furoate 27.5 mug, or placebo to alleviate th
7 randomly assigned to initiate treatment with fluticasone furoate and vilanterol (n=2114) or usual car
8 V1) and the increased risk of pneumonia with fluticasone furoate and vilanterol compared with vilante
9 ightened cardiovascular risk, treatment with fluticasone furoate and vilanterol did not affect mortal
10 hose on usual care (977 [71%] of 1373 in the fluticasone furoate and vilanterol group vs 784 [56%] of
11 f a once-daily treatment regimen of combined fluticasone furoate and vilanterol improved asthma contr
12 Across all doses of inhaled corticosteroids, fluticasone furoate and vilanterol reduced exacerbations
13 er for patients who initiated treatment with fluticasone furoate and vilanterol than for those on usu
14 fractures were reported more frequently with fluticasone furoate and vilanterol than with vilanterol
15 , a once-daily treatment regimen of combined fluticasone furoate and vilanterol was associated with a
17 patients (605 assigned to usual care, 602 to fluticasone furoate and vilanterol) had a baseline ACT s
18 ms (fluticasone propionate and salmeterol or fluticasone furoate and vilanterol); a control arm (not
19 nts from baseline in patients initiated with fluticasone furoate and vilanterol, compared with 2.8 po
21 a combined treatment of the corticosteroid, fluticasone furoate, and the long-acting beta agonist, v
22 COPD to a once-daily inhaled combination of fluticasone furoate at a dose of 100 mug and vilanterol
23 ear [95% CI 1-15]) with similar findings for fluticasone furoate (difference 8 mL per year [95% CI 1-
24 the once-daily inhaled corticosteroid (ICS) fluticasone furoate (FF) and long-acting beta(2) -agonis
26 Genotyping and imputation was performed in fluticasone furoate (FF) or fluticasone propionate-treat
27 ontrolled trial, once-daily inhaled placebo, fluticasone furoate (FF; 100 mug), vilanterol (VI; 25 mu
28 tion; 4111 in the placebo group, 4135 in the fluticasone furoate group, 4118 in the vilanterol group,
29 18% in the combination group, and 17% in the fluticasone furoate group, and 17% in the vilanterol gro
30 roup, 6% in the combination group, 5% in the fluticasone furoate group, and 4% in the vilanterol grou
31 ative reduction; p=0.137) or the components (fluticasone furoate, HR 0.91 [0.77-1.08]; p=0.284; vilan
32 vilanterol plus 50 mug, 100 mug, or 200 mug fluticasone furoate in patients with moderate-to-severe
36 aring 24 weeks of once-daily triple therapy (fluticasone furoate/umeclidinium/vilanterol 100 mug/62.5
37 mug and vilanterol at a dose of 25 mug (the fluticasone furoate-vilanterol group) or to usual care (
39 (95% confidence interval, 1.1 to 15.2), with fluticasone furoate-vilanterol therapy than with usual c
40 led corticosteroid/long-acting beta2-agonist fluticasone furoate/vilanterol 100/25 mug or placebo (7-
41 bation rate was noted between the 200/25 mug fluticasone furoate/vilanterol group and the vilanterol
42 ight deaths from pneumonia were noted in the fluticasone furoate/vilanterol groups compared with none
43 e and severe exacerbations were noted in all fluticasone furoate/vilanterol groups than in the vilant
44 e and severe exacerbations were noted in all fluticasone furoate/vilanterol groups than in the vilant
47 led combination of either 100 mug or 200 mug fluticasone furoate with 25 mug vilanterol or optimised
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。